T1	intervention 76 89	pegfilgrastim
T2	control 103 113	filgrastim
T3	ethinicity 117 124	Chinese
T4	eligibility 125 174	breast cancer patients receiving TAC chemotherapy
T5	location 799 804	China
T6	No-of-participants 814 817	171
T7	outcome-Measure 1124 1130	safety
T8	outcome-Measure 1111 1119	Efficacy
T9	outcome 1169 1206	mean duration of grade 3+ neutropenia
T10	outcome 1431 1464	incidence of grade 3+ neutropenia
T11	outcome 1565 1636	febrile neutropenia, time to neutrophil recovery and neutrophil profile
T12	outcome 1693 1708	safety profiles
